Search for a command to run...
BACKGROUND: Despite the increasing number of patients with secondary immunodeficiency disorders (SIDs), reliable data on their prevalence, diagnostic criteria, and treatment are lacking, which underscores the requirement for research in this area. AIMS: To characterize the clinical and immunological features, and treatment approaches for various forms of SIDs observed in clinical practice. MATERIALS AND METHODS: A retrospective analysis of medical records from 180 patients with a confirmed diagnosis of SIDs was conducted. The database included information on primary and comorbid conditions, the scope of administered therapy, characterization of SIDs clinical signs, data from general clinical and immunological investigations, and specific treatment options for SIDs. RESULTS: Three groups of patients with SIDs were identified: patients with oncohematological diseases (group 1) - 51 people (34.0%), group 2 - patients with chronic bacterial infections 33 people (22.0%), group 3 - patients with chronic viral infections - 41 people (27.3%). In Group 1, lymphomas accounted for 82.3% of the underlying pathologies. Manifestations of infectious syndrome in 80.3% were associated with respiratory tract disorders, with pneumonia diagnosed in 21.5%. This cohort showed a significant B-lymphocytopenia, associated with reduced IgG levels, alongside phagocytosis depression. SIDs was managed with intravenous immunoglobulin (IVIG). In Group 2, respiratory tract, skin, and soft tissue lesions (57.6% and 36.4%, respectively) occurred in the setting of depressed phagocytosis, necessitating more frequent antibacterial therapy. However, patients with oncohematological diseases had 3.2 times higher odds of developing recurrent infections requiring prolonged or parenteral antibiotic therapy (OR = 3.257 [CI 1.303-8.142] p = 0.01300). For SIDs correction, azoximer bromide was prescribed to 66.6% of patients The majority of patients in Group 3 (97.5%; n=40) had infection induced by various types of herpes viruses, with frequent relapses and resistance to standard therapy. Laboratory assessment revealed reduced phagocytic indices CONCLUSIONS: The study demonstrates the relevance of the problem of SIDs in clinical practice, which requires a multidisciplinary approach and the involvement of physicians of various specialties, followed by rational patient referral to a specialized clinical immunology center.